10-K: OmniAb Reports 2025 Revenue Decline Amidst Strategic Tech Expansion

OmniAb, Inc. reported a 29% decrease in total revenue and an increased net loss for fiscal year 2025, despite growth in active partnerships and the launch of new antibody discovery technologies.

Summary

• Total revenue for the fiscal year ended December 31, 2025, decreased by 29% to $18.7 million, down from $26.4 million in 2024.
• Net loss increased to $64.8 million in 2025, compared to $62.0 million in 2024.
• Active partners grew to 107 as of December 31, 2025, up from 91 in 2024.
• Active programs increased to 407 as of December 31, 2025, from 363 in 2024.
• The number of OmniAb-derived antibodies in clinical development by partners remained at 27, with 2 under regulatory review and 3 approved products.
• Research and development expenses decreased by 13% to $47.754 million in 2025, including $3.9 million in impairment charges related to small molecule ion channel assets and prepaid research technology.
• General and administrative expenses decreased by 5% to $29.215 million, primarily due to lower legal fees and share-based compensation.
• The company completed a private placement (PIPE) in August 2025, raising approximately $30.0 million in gross proceeds.
• Workforce reductions impacted 22 employees during 2025, resulting in $1.9 million in restructuring charges.
• Cash, cash equivalents, and short-term investments totaled $54.0 million as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with mixed sentiment. While the significant decline in revenue and increased net loss are concerning, the growth in active partners and programs, along with strategic investments in new technologies and a successful capital raise, suggest underlying business development and long-term potential.

Positives

• Active partners increased to 107 as of December 31, 2025, up from 91 in 2024, indicating expanding market penetration and future opportunities.
• Active programs grew to 407 as of December 31, 2025, from 363 in 2024, suggesting increased utilization of the OmniAb technology platform.
• Royalty revenue increased by 52% to $878 thousand in 2025, driven by higher net sales from partners' product sales in China, signaling potential for long-term value.
• Launched OmniHub in December 2024, a high-dimensional unified bioinformatics portal designed to enhance antibody discovery efficiency.
• Launched OmniUltra in 2025, extending the platform beyond traditional antibody modalities into the peptide space, including picobodies.
• Launched the xPloration Partner Access Program in May 2025, allowing partners to purchase instruments and license AI-powered software, generating new xPloration revenue of $754 thousand.
• Successfully completed an August 2025 PIPE offering, raising approximately $30.0 million in gross proceeds, strengthening liquidity.
• Achieved a gain of $3.0 million from the sale of a small molecule Kv7.2 program to Angelini in May 2025.

Negatives

• Total revenue decreased significantly by 29% to $18.7 million in 2025 from $26.4 million in 2024.
• Net loss increased to $64.8 million in 2025, up from $62.0 million in 2024, indicating continued unprofitability.
• License and milestone revenue declined by 30% to $9.771 million in 2025, primarily due to a $1.6 million decline in milestone revenue and a $2.5 million decline in license revenue.
• Service revenue decreased by 39% to $7.263 million, mainly due to the completion or discontinuation of certain small molecule ion channel programs.
• Incurred $3.3 million in impairment charges related to certain ion channel property and equipment and $0.6 million for prepaid research technology in 2025.
• Workforce reductions impacted 22 employees during 2025, leading to $1.9 million in restructuring charges.
• Warrants are currently 'out-of-the money,' with an exercise price of $11.50 per share, meaning warrant holders are unlikely to exercise, limiting potential cash proceeds.
• Dependence on a limited number of partners for a significant portion of revenue (37% from three partners in 2025).

Risks

• Partners may not achieve projected discovery and development milestones or commercialize products, impacting downstream payments and royalties.
• Commercial success depends on the quality and acceptance of the antibody discovery platform by new and existing partners.
• Future success is dependent on the approval and commercialization of products by partners, over which the company has no control regarding clinical development, regulatory strategy, or commercialization efforts.
• Inability to maintain and expand current partnerships and enter into new ones could adversely affect future operating results.
• Continued net losses are expected, and the company may not generate sufficient revenue to achieve and maintain profitability.
• Operating results may fluctuate significantly due to various factors, making future results difficult to predict.
• The life sciences and biotech platform technology market is highly competitive, potentially hindering revenue growth or profitability.
• Reliance on third parties to host mouse and rat colonies and supply materials could lead to delays or impairment of programs.
• Inability to obtain and maintain sufficient intellectual property protection could allow competitors to develop similar technologies.
• Reliance on in-licenses from third parties means loss of these rights could materially and adversely affect the business.
• Unstable market and economic conditions, including adverse developments with financial institutions, may impact the business and stock price.
• The market price of common stock and warrants is likely to be highly volatile.
• Sales of a substantial number of securities by existing securityholders could cause stock and warrant prices to fall.
• Platform utilizes animals, which could contract disease or die, interrupting business operations or harming reputation.
• Investments in research and development are inherently risky and may not generate expected returns.
• Third-party payor coverage and reimbursement status of newly approved therapeutics is uncertain, limiting partners' commercialization ability.
• Healthcare reform efforts, such as the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act, may lower biopharmaceutical product prices and impact profitability.
• U.S. legislation, sanctions, tariffs, and foreign regulatory requirements (e.g., BIOSECURE Act) could increase costs or impact supply from foreign CROs/CMOs.
• Reliance on a limited number of suppliers for equipment and materials could lead to interruptions.
• Failure to adapt to rapid technological change and new competitor products could make the platform less desirable.
• Dependence on information technology systems means failures could harm the business and reputation.
• Inability to attract and retain highly qualified management and scientific personnel could adversely affect operations.
• Future acquisitions or investments could negatively affect operating results, dilute ownership, or incur debt/expense.
• Damage or inoperability of operating facilities could jeopardize research and development efforts.
• Insurance policies may be insufficient to cover all business risks, leading to significant uninsured liabilities.
• Security breaches, data loss, and other disruptions could compromise sensitive information and expose the company to liability.
• Business could become subject to more extensive government regulation than currently anticipated, increasing compliance costs and uncertainty.
• Business operations and relationships may be subject to fraud and abuse and other healthcare laws and regulations, leading to sanctions or penalties.
• Changes in and failures to comply with data privacy, security, and protection laws (e.g., GDPR, CCPA, EU AI Act) may adversely affect business.
• Portfolio of investments or bank deposits may be subject to market, interest, and credit risk.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Inability to protect the confidentiality of information and trade secrets could harm the business.
• Claims that employees, consultants, or contractors wrongfully used or disclosed confidential information of third parties could arise.
• Inability to protect and enforce trademarks and trade names could harm competitive position.
• Claims challenging the inventorship of patents and other intellectual property could lead to litigation.
• Litigation related to intellectual property could be time-intensive and costly.
• Compliance with governmental patent agency procedures is required to maintain patent protection, and non-compliance could lead to loss of rights.
• Patent terms may be inadequate to protect competitive position for an adequate amount of time.
• Use of open source software could compromise ability to offer data packages and lead to litigation.
• Intellectual property discovered through government-funded programs may be subject to federal regulations like march-in rights.
• Employees, consultants, and partners may engage in misconduct or improper activities.
• Use of biological and hazardous materials requires expertise and expense for handling, storage, and disposal, and may result in claims.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• Significant costs are incurred as a public company, and management must devote substantial time to compliance initiatives.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Failure to meet Nasdaq listing requirements could result in delisting.
• Business is subject to risks from pandemic and epidemic diseases.
• Provisions in the certificate of incorporation and Delaware law could discourage a takeover and lead to entrenchment of management.
• Exclusive forum provision in the certificate of incorporation and warrant agreement could limit stockholders' and warrant holders' ability to obtain a favorable judicial forum.

Future Outlook

OmniAb anticipates continued losses in the foreseeable future as it invests in enhancing its OmniAb technology platform and expanding its market reach. The company believes its long-term value will be driven by royalties from successful partner programs, while short-term revenue will be materially driven by milestones and services. The company plans to continue investing in enabling technologies and evaluating strategic acquisitions to broaden its capabilities in antibody and other target-binding protein discovery.

Management Comments

• "We believe the OmniAb animals comprise the most diverse host systems available in the industry."
• "We believe the long-term value of our business will be driven by royalties given that such payments are based on global sales of potential future partner programs, which generally provide for larger and recurring payments as compared to technology access, research fees and milestone payments."
• "We believe our revenue will be materially driven by milestones and services in the shorter term, and by royalties in the longer term, from our partnered programs."
• "We expect to continue to incur losses for the foreseeable future as we invest in research and development activities to improve our OmniAb technology platform and market and sell our technologies to existing and new partners."
• "We believe our existing cash, cash equivalents and short-term investments are sufficient to support our operations through at least the next 12 months."

Industry Context

StockSavvy.ai notes that OmniAb operates within a rapidly growing antibody therapeutics market, which reached approximately $250 billion in sales in 2023 and is projected to surpass $330 billion by 2029, according to Clarivate Analytics Cortellis. The industry is seeing accelerated investment, with the number of antibodies in clinical development increasing from 572 in 2018 to 1,430 in 2024 (17% CAGR). Regulatory changes like the Inflation Reduction Act (IRA) incentivize biological products over small molecules, potentially benefiting OmniAb's platform. However, the market is highly competitive, with numerous companies offering transgenic animal platforms, single-cell screening, and antibody engineering solutions, including AbCellera Biologics Inc., Regeneron Pharmaceuticals, Inc., and Charles River Labs Inc. The increasing application of AI tools across R&D workstreams also presents an evolving landscape and potential new cybersecurity risks.

Comparison to Industry Standards

• Monoclonal antibodies and monoclonal antibody conjugate drugs have a 12.1% likelihood of receiving market authorization from Phase 1 clinical trials, higher than small molecule modalities at 7.5%, according to BIO's Clinical Development Success Rates and Contributing Factors 2011-2020. OmniAb's focus on antibody discovery aligns with this higher success rate.
• The company's multi-species platform (OmniRat, OmniChicken, OmniMouse, OmniTaur) is presented as unique, with OmniAb being the only platform offering transgenic mouse, rat, and chicken technologies, in addition to cow antibody humanization technology, differentiating it from competitors like AbCellera Biologics Inc., Ablexis LLC, and Regeneron Pharmaceuticals, Inc. that primarily focus on genetically-engineered rodents.
• OmniAb's xPloration platform is positioned as providing industry-leading screening and cell recovery compared to other spatial separation techniques and systems that evaluate a smaller percentage of a repertoire, such as those offered by Bruker Corporation or Sartorius AG.
• The company's established core competency in ion channels and transporters differentiates its technology, addressing challenging targets that competitors like Charles River Labs Inc. and Evotec SE also pursue.

Corporate Governance

Legal Proceedings

• Not currently a party to or aware of any proceedings that are believed to have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• Affiliates of Avista Capital Partners own 11.0% of outstanding common stock and warrants to purchase 11,345,489 shares, potentially creating conflicts of interest with public stockholders.
• Certain existing stockholders, including the Sponsor, purchased shares at a significantly lower price ($0.004 per share for Founder Shares) than the current trading price, giving them a substantial potential profit margin even if the public trading price declines.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity raises and warrant exercises, high stock price volatility, and no anticipated cash dividends. Existing securityholders may sell shares, causing price declines.
• **Employees**: Experienced workforce reductions (22 employees) in 2025, but the company aims to attract and retain talent through competitive pay, benefits (equity awards, subsidized health insurance, 401(k) matching, education reimbursement), and professional development.
• **Partners**: The company's success is highly dependent on partners' ability to successfully develop and commercialize therapeutics, with risks if partners fail to meet milestones or terminate agreements. New technologies like OmniHub and OmniUltra aim to enhance partner experience and discovery efficiency.
• **Customers**: Benefit from access to cutting-edge discovery research technology, including new platforms like OmniHub and OmniUltra, and the xPloration Partner Access Program, designed to accelerate drug development and reduce costs.
• **Creditors**: The company's ability to meet liquidity requirements depends on cash flows from operations and potential additional capital raises, which could involve debt financing with restrictive covenants.

Next Steps

• Continue to identify and capture new opportunities with existing partners by building upon trusted relationships.
• Increase the number of partnerships through increased business development activities and technological expansion.
• Further technological differentiation through intelligent expansion and innovation, including evaluating strategic technology acquisitions.
• Invest in enabling technologies to broaden capabilities in antibody and other target-binding protein discovery.
• Management will continue to implement and improve managerial, operational, and financial systems, invest in facilities, and recruit/train qualified personnel to manage anticipated growth.
• Monitor compliance with applicable financial reporting standards and review new pronouncements.

Key Dates

Recommendation

OmniAb's 2025 financial results show a significant decline in revenue and an increased net loss, which are negative short-term indicators. However, the company is actively expanding its technology platform with new product launches (OmniHub, OmniUltra, xPloration Partner Access Program) and growing its active partner and program base, which are crucial for long-term value creation through royalties. The recent PIPE offering provides necessary capital, but the warrants being out-of-the-money limits immediate cash infusion from exercises. Given the mixed signals of short-term financial weakness against strategic long-term growth initiatives and a volatile market, a 'hold' recommendation is appropriate. Investors should monitor the progression of partnered programs, the impact of new technologies on revenue generation, and the company's path to profitability.

Keywords

Antibody Discovery, Biotechnology, SEC Filing, 10-K, Financial Report, Transgenic Animals, OmniAb Platform, Drug Development, Pharmaceutical, AI in Biotech, Machine Learning, Ion Channels, Therapeutics, Biological Intelligence, xPloration, OmniHub, OmniUltra, Milestone Payments, Royalties, Net Loss, Revenue Decline, Capital Raise, Intellectual Property, Corporate Governance, Risk Factors